We hypothesized that upregulation of VANGL2 disrupts canonical and noncanonical signaling pathways and underlies the clinical phenotypes observed in patients with BOS and other mutations in ASXL. The gene discussed is VANGL2; the disease is Buschke-Ollendorff syndrome.